Home Pipeline

Overview

MacroGenics has a diverse portfolio of proprietary product candidates with several clinical trials currently underway or planned for the near future. Set forth below is the company’s development pipeline of product candidates for which we have retained commercialization or co-promotion rights in the U.S. or more broadly.

Program (Target)
Indications
Pre-IND Phase 1 Phase 2 Phase 3 Partner Our Commercial Rights
Oncology
Margetuximab (HER2) Green Cross Worldwide,
except Korea
Breast (HER2+) “SOPHIA”
placeholder
placeholder
placeholder
placeholder
Gastric (+anti-PD-1)
placeholder
placeholder
placeholder
Flotetuzumab (CD123 x CD3) Servier North America,
Japan, Korea, India
AML/MDS
placeholder
placeholder
AML (+MGA012)
placeholder
Planned
MGA012 (PD-1) Incyte*
Solid Tumors
placeholder
placeholder
MGD013 (PD-1 x LAG-3) Worldwide
Solid Tumors/Heme
placeholder
placeholder
MGD019 (PD-1 x CTLA-4) Worldwide
Solid Tumors
placeholder
Enoblituzumab (B7–H3) Worldwide
Solid Tumors (+anti-PD-1)
placeholder
placeholder
placeholder
Neoadjuvant Prostate
placeholder
placeholder
MGD009 (B7-H3 x CD3) Worldwide
Solid Tumors
placeholder
placeholder
Solid Tumors (+MGA012)
placeholder
placeholder
MGC018 (B7-H3) Worldwide
ADC/Solid Tumors
placeholder
MGD007 (gpA33 x CD3) Servier North America,
Japan, Korea, India
Colorectal
placeholder
placeholder
AUTOIMMUNE & INFECTIOUS DISEASES
Teplizumab (CD3) NIDDK/NIH Worldwide
Type 1 Diabetes Prev.
placeholder
placeholder
placeholder
MGD010 (CD32B x CD79B) Worldwide
Autoimmune Disorders
placeholder
placeholder
MGD014 (HIV x CD3) NIAID/NIH Worldwide
HIV
placeholder
placeholder

Oncology
Breast (HER2+) “SOPHIA”
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
placeholder
placeholder
Gastric (+anti-PD-1)
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
placeholder

PartnerGreen Cross
Our Commercial RightsWorldwide, except Korea
AML/MDS
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
AML (+MGA012)
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
Planned
PartnerServier
Our Commercial RightsNorth America, Japan, Korea, India
Solid Tumors
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
PartnerIncyte*
Our Commercial Rights
Solid Tumors/Heme
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
Our Commercial RightsWorldwide
Solid Tumors
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
Our Commercial RightsWorldwide
Solid Tumors (+anti-PD-1)
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
placeholder
Neoadjuvant Prostate
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
Our Commercial RightsWorldwide
Solid Tumors
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
Solid Tumors (+MGA012)
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
Our Commercial RightsWorldwide
ADC/Solid Tumors
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
Our Commercial RightsWorldwide
Colorectal
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
PartnerServier
Our Commercial RightsNorth America, Japan, Korea, India

AUTOIMMUNE & INFECTIOUS DISEASES
Type 1 Diabetes Prev.
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
placeholder
PartnerNIDDK/NIH
Our Commercial RightsWorldwide
Autoimmune Disorders
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
Partner
Our Commercial RightsWorldwide
HIV
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
PartnerNIAID/NIH
Our Commercial RightsWorldwide

placeholdermAb placeholderDARTplaceholderADC
*MacroGenics retains rights to develop its pipeline assets in combination with MGA012 and to manufacture a portion of global clinical and commercial supply needs of MGA012.

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close